Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer

Annals of Surgical Oncology

Volumn 19, Issue 7, 2012, Pages 2352-2359

  Ceelen, Wim P ^a   Van Nieuwenhove, Yves ^a   Van Belle, Simon ^a   Denys, Hannelore ^a   Pattyn, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; OXALIPLATIN; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; EXTENSIVE CYTOREDUCTION SURGERY; FEMALE; FOLLOW UP; GASTRECTOMY; HEMICOLECTOMY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION; LIVER RESECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARY CANCER; OVERALL SURVIVAL; PERITONECTOMY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMALL INTESTINE RESECTION; SPLENECTOMY; STOMA; SURGICAL TECHNIQUE; URETER SURGERY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

EID: 84865127578     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0878-6     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18:581-92. (Pubitemid 46359643)
3. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2006;95:S161-92.
4. Leitao MM, Chi DS. Surgical management of recurrent ovarian cancer. Semin Oncol. 2009;36:106-11.
5. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: ameta-analysis. Gynecol Oncol. 2009;112:265-74.
6. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324-30.
7. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-5. (Pubitemid 26428219)
8. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-7. (Pubitemid 32176274)
9. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cis-platin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43. (Pubitemid 43048949)
10. Spratt JS, Adcock RA, Muskovin M, Sherrill W, Mckeown J. Clinical delivery system for intra-peritoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-60. (Pubitemid 10140145)
11. Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44:2546-54.
12. Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813-21.
13. Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004;94:325-32. (Pubitemid 39024534)
14. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cy-toreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18:1943-50. (Pubitemid 350286229)
15. Swellengrebel HAM, Verwaal VJ, Smeenk RM, Antonini N, Zoetmulder FAN. Quantitative intra-operative assessment of peritoneal carcinomatosis-a comparison of three prognostic tools. Eur J Cancer. Suppl 2007;5:258.
16. Ray-Coquard I, Weber B, Cretin J, et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer. 2009;100:601-7.
17. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790-6. (Pubitemid 30013658)
18. Elias D, Bonnay A, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267-72. (Pubitemid 34704979)
19. De Somer F, Ceelen W, Delanghe J, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int. 2008;28:61-6. (Pubitemid 351566127)
20. Ceelen WP, Peeters M, Houtmeyers P, et al. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:535-41. (Pubitemid 351643030)
21. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144-53. (Pubitemid 30027690)
22. Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreduc-tive surgery for localized, recurrent epithelial ovarian cancer-analysis of prognostic factors and survival outcome. Cancer. 2007;109:685-91. (Pubitemid 46233229)
23. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-61. (Pubitemid 38325942)
24. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702-10. (Pubitemid 44951480)
25. Ceelen W, Flessner M. Intraperitoneal cytotoxic drug therapy for tumours confined to the peritoneal cavity: biophysical principles and clinical evidence. Nat Rev Clin Oncol. 2009. doi: 10.1038/nrclinonc.2009.217.
26. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004; 22:3284-92. (Pubitemid 41103684)
27. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69-76. (Pubitemid 43025395)
28. Sugarbaker PH. Cytoreductive surgery and perioperative intra-peritoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Curr Opin Obstet Gynecol. 2009; 21:15-24.
29. Jacquet P, Stephens AD, Averbach AM, et al. Sugarbaker PH. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996;77: 2622-9.
30. Crawford SC, Vasey PA, Paul J, et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005;23:8802-11. (Pubitemid 46211526)
31. Kohandel M, Sivaloganathan S, Oza A. Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy. J Theor Biol. 2006;242:62-8. (Pubitemid 44188775)
32. Zenasni F, Botella M, Elias D, et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer. 2009;17:1255-61.
33. Markman M. Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: a critical need for an evidence-based evaluation. Gynecol Oncol. 2009;113:4-5.
34. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis-a Hoosier Oncology Group trial. Cancer. 2008;113:723-32.
35. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001;61:2929-34. (Pubitemid 32691937)
36. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal car-cinomatosis from ovarian cancer. World J Surg. 2004;28:1040-5. (Pubitemid 40109891)
37. Reichman TW, Cracchiolo B, Sama J, et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol. 2005;90:51-6. (Pubitemid 40594099)
38. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006;94:316-24. (Pubitemid 44330855)
39. Raspagliesi F, Kusamura S, Torres JCC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32:671-5. (Pubitemid 44063998)
40. Helm CW, Toler CR, Martin RS, et al. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endo-metrial carcinoma recurrent within the peritoneal cavity. Int J Gynecol Cancer. 2007;17:204-9. (Pubitemid 46217718)
41. Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315-25.
42. Fagotti A, Paris B, Grimolizzi F, et al. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol. 2009;113: 335-40.